Chargement en cours...
Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
PURPOSE: We tried to evaluate whether there are any specific features in treatment outcomes of firstline afatinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), compared with gefitinib or erlotinib. MATERIALS AND METHODS: We analyzed patients trea...
Enregistré dans:
| Publié dans: | Cancer Res Treat |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Korean Cancer Association
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6473268/ https://ncbi.nlm.nih.gov/pubmed/29898592 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2018.117 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|